{
    "clinical_study": {
        "@rank": "156511", 
        "arm_group": [
            {
                "arm_group_label": "Selumetinib 75mg", 
                "arm_group_type": "Experimental", 
                "description": "Volunteers will receive selumetinib 75mg administered by mouth, as a capsule"
            }, 
            {
                "arm_group_label": "Moxifloxacin 400 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Volunteers will receive moxifloxacin 400mg administered by mouth, as a capsule"
            }, 
            {
                "arm_group_label": "Selumetinib 75mg placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Volunteers will receive selumetinib 75mg placebo, administered by mouth, as a capsule."
            }
        ], 
        "brief_summary": {
            "textblock": "Study to assess the effect of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc\n      interval in healthy male volunteers."
        }, 
        "brief_title": "To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumours", 
        "detailed_description": {
            "textblock": "A double-blind (Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), Placebo-controlled,\n      Open-Label (Moxifloxacin) Positive-controlled, Randomized, Three-period Crossover Study to\n      Assess the Effects of Single Oral Dose of Selumetinib (75 mg) on QTc Interval Compared to\n      Placebo, using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: 1. Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at\n        least 50 kg and no more than 100 kg (inclusive). 2. Must  have not smoked in the last 30\n        days prior to screening for this study. 3. Have a calculated creatinine clearance (CrCL)\n        greater than 50 mL/min using the Cockcroft-Gault formula.\n\n        Exclusion Criteria: 1. Subjects of Japanese or non-Japanese Asian ethnicity. 2. Subjects\n        where any one parent or grandparent (maternal or paternal) is Japanese or non-Japanese\n        Asian (e.g. China, Taiwan, Korea, Philippines, Thailand, Vietnam, and Malaysia). Asian\n        Indians are acceptable. 3. Past history of central serous retinopathy or retinal vein\n        thrombosis,intraocular pressure greater than 21 mmHg or uncontrolled glaucoma. 4. Any\n        clinically relevant abnormal findings in physical examination, hematology, clinical\n        chemistry, urinalysis, vital signs or ECG at baseline in the opinion of the investigator.\n        5. History or presence of any clinically significant disease or disorder in the opinion of\n        the investigator."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02056392", 
            "org_study_id": "D1532C00071"
        }, 
        "intervention": [
            {
                "arm_group_label": "Selumetinib 75mg", 
                "description": "Volunteers will receive 75 mg selumetinib oral dose (Treatment A)", 
                "intervention_name": "Selumetinib", 
                "intervention_type": "Drug", 
                "other_name": "AZD6244"
            }, 
            {
                "arm_group_label": "Moxifloxacin 400 mg", 
                "description": "Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)", 
                "intervention_name": "Moxifloxacin", 
                "intervention_type": "Drug", 
                "other_name": "Avelox\u00ae"
            }, 
            {
                "arm_group_label": "Selumetinib 75mg placebo", 
                "description": "Volunteers will receive selumetinib placebo oral dose (Treatment C)", 
                "intervention_name": "selumetinib", 
                "intervention_type": "Drug", 
                "other_name": "AZD6244"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Phase I, healthy, pharmacokinetics", 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I, Double-blind (Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), Placebo-controlled, Open-Label (Moxifloxacin) Positive-controlled, Randomized, Three-period Crossover Study to Assess the Effects of Single Oral Dose of Selumetinib (75 mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Aged 18 to 45 Years", 
        "other_outcome": {
            "description": "Assessments performed during each of the 3 treatments", 
            "measure": "Safety variables (adverse events, physical examinations, ophthalmic assessments, vital signs, clinical laboratory assessments and 12 lead electrocardiograms)", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline (Day -1) up to Day 28"
        }, 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Quintiles Drug Research Unit Call Centre", 
            "phone": "0800 634 1132"
        }, 
        "overall_official": {
            "affiliation": "Quintiles 6700 W 115th Street, Kansas, US", 
            "last_name": "Scott Rasmussen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Performed during each of the 3 treatments", 
            "measure": "Effect of a single dose of selumetinib (75 mg) on the change in time-matched QTcF interval compared to placebo.", 
            "safety_issue": "Yes", 
            "time_frame": "Digital ECGs recorded pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02056392"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Curve taken during each of the 3 treatments", 
                "measure": "Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of area under the plasma concentration-time from time zero to infinity (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Curve taken during each of the 3 treatments", 
                "measure": "Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration AUC(0-t)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Curve taken during each of the 3 treatments", 
                "measure": "Pharmacokinetics of selumetinib and moxifloxacin only, by assessment of apparent volume of distribution at equilibrium, mean residence time (MRT)*CL/F (Vss/F)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Curve taken during each of the 3 treatments", 
                "measure": "Pharmacokinetics of selumetinib and moxifloxacin only, by assessment of apparent systemic plasma clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Curve taken during each of the 3 treatments", 
                "measure": "Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of apparent terminal phase of volume at distribution (selumetinib and moxifloxacin only) (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Curve taken during each of the 3 treatments", 
                "measure": "Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of terminal half-life (t1/2).", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Curve taken during each of the 3 treatments", 
                "measure": "Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of terminal rate constant (\u03bbz)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Curve taken during each of the 3 treatments", 
                "measure": "Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of mean residence time (MRT)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Curve taken during each of the 3 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assessment of AUC metabolite to parent ratio, N-desmethyl selumetinib (MRAUC)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Curve taken during each of the 3 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N-desmethyl selumetinib by assessment of Cmax metabolite to parent ratio, N-desmethyl selumetinib (MRCmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Curve taken during each of the 3 treatments", 
                "measure": "Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of time to Cmax (tmax).", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Curve taken during each of the 3 treatments", 
                "measure": "Pharmacokinetics of selumetinib, N-desmethyl selumetinib, and moxifloxacin by assessment of maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48 hours post dose"
            }, 
            {
                "description": "Performed during each of the 3 treatments", 
                "measure": "The effect of selumetinib on additional ECG variables (QT, HR, RR, QRS, PR) and QTcB", 
                "safety_issue": "Yes", 
                "time_frame": "Digital ECGs recorded pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose"
            }, 
            {
                "description": "Performed during each of the 3 treatments", 
                "measure": "The maximum of the mean changes in time-matched QTcF interval after moxifloxacin administration compared to placebo", 
                "safety_issue": "Yes", 
                "time_frame": "Digital ECGs recorded pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post dose"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}